SG Americas Securities LLC Has $42.58 Million Holdings in Quest Diagnostics Incorporated $DGX

SG Americas Securities LLC lifted its holdings in Quest Diagnostics Incorporated (NYSE:DGX) by 20.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 217,286 shares of the medical research company’s stock after purchasing an additional 37,633 shares during the quarter. SG Americas Securities LLC’s holdings in Quest Diagnostics were worth $42,584,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Quattro Advisors LLC bought a new position in Quest Diagnostics in the fourth quarter valued at $25,000. JFS Wealth Advisors LLC lifted its position in Quest Diagnostics by 114.3% during the 4th quarter. JFS Wealth Advisors LLC now owns 150 shares of the medical research company’s stock worth $26,000 after buying an additional 80 shares in the last quarter. Harbor Investment Advisory LLC lifted its position in Quest Diagnostics by 113.7% during the 4th quarter. Harbor Investment Advisory LLC now owns 156 shares of the medical research company’s stock worth $27,000 after buying an additional 83 shares in the last quarter. DV Equities LLC acquired a new position in shares of Quest Diagnostics during the 4th quarter worth about $27,000. Finally, Sittner & Nelson LLC acquired a new position in shares of Quest Diagnostics during the 4th quarter worth about $29,000. Institutional investors and hedge funds own 88.06% of the company’s stock.

Insider Activity

In other news, CEO J. E. Davis sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the transaction, the chief executive officer directly owned 132,423 shares of the company’s stock, valued at approximately $25,708,601.22. This trade represents a 7.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of Quest Diagnostics stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the completion of the sale, the senior vice president owned 13,510 shares of the company’s stock, valued at approximately $2,702,000. The trade was a 37.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.88% of the stock is owned by insiders.

Quest Diagnostics Price Performance

Quest Diagnostics stock opened at $196.92 on Wednesday. Quest Diagnostics Incorporated has a 12 month low of $164.65 and a 12 month high of $213.50. The stock’s 50 day moving average is $195.00 and its 200-day moving average is $192.37. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $21.80 billion, a price-to-earnings ratio of 21.76, a PEG ratio of 2.31 and a beta of 0.59.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings results on Tuesday, April 21st. The medical research company reported $2.50 earnings per share for the quarter, topping the consensus estimate of $2.37 by $0.13. The business had revenue of $2.90 billion during the quarter, compared to analysts’ expectations of $2.83 billion. Quest Diagnostics had a return on equity of 15.60% and a net margin of 9.07%.The firm’s revenue for the quarter was up 9.2% compared to the same quarter last year. During the same period last year, the firm posted $1.94 EPS. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. Equities research analysts expect that Quest Diagnostics Incorporated will post 10.72 EPS for the current year.

Quest Diagnostics Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 22nd. Shareholders of record on Wednesday, July 8th will be paid a $0.86 dividend. The ex-dividend date is Wednesday, July 8th. This represents a $3.44 annualized dividend and a yield of 1.7%. Quest Diagnostics’s payout ratio is 38.01%.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on DGX shares. Weiss Ratings raised Quest Diagnostics from a “buy (b)” rating to a “buy (b+)” rating in a research report on Tuesday, June 9th. Truist Financial increased their price target on Quest Diagnostics from $220.00 to $225.00 and gave the company a “hold” rating in a research report on Wednesday, April 22nd. Jefferies Financial Group restated a “buy” rating and issued a $225.00 price target on shares of Quest Diagnostics in a research note on Tuesday, April 21st. Barclays boosted their price target on Quest Diagnostics from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 22nd. Finally, Evercore set a $225.00 price objective on Quest Diagnostics in a research note on Tuesday, April 21st. Seven investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $216.58.

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.